Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Clinical Trials
12
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2013
Active, not recruiting
4
33.3%
Available
1
8.3%
Completed
2
16.7%
No Longer Available
1
8.3%
Recruiting
3
25.0%
Terminated
1
8.3%
No approval data available
- Ocugen's investigational modifier gene therapy OCU400 received provisional approval and priority designation from The Bahamas' Longevity and Regenerative Therapies Board for retinitis pigmentosa. - Ocugen plans to supply OCU400 through an expanded access program and aims to treat the first retinitis pigmentosa patient within 90 days of full LARTA Board approval. - OCU400 is in Phase 3 development for a broad retinitis pigmentosa indication with enrollment complete and topline data expected in the first quarter of 2027. - The NR2E3-based therapy targets retinal diseases linked to mutations in more than 100 genes and holds FDA RMAT and orphan drug designations plus EMA orphan status.
- Ocugen outlined timelines for three planned Biologics License Applications with the FDA, all targeting serious eye disorders with few adequate treatment options. - OCU400 for retinitis pigmentosa is slated for top-line data in the first quarter of 2027, with a BLA submission to follow immediately. - OCU410ST for Stargardt disease expects pivotal data in the second quarter of 2027, while OCU410 for geographic atrophy in dry AMD files at the end of 2028.
- The Dry Age-Related Macular Degeneration market across the 7MM is projected to grow at a 19.2% CAGR through 2036, driven by novel therapies and rising disease prevalence exceeding 72 million AMD cases in 2025. - Emerging oral therapies like Tinlarebant and Gildeuretinol acetate target vitamin A–driven retinal toxicity, offering alternatives to chronic intravitreal injections required by approved complement inhibitors IZERVAY and SYFOVRE. - Ocugen reported a statistically significant 31% reduction in GA lesion growth in its Phase II ArMaDa trial for gene therapy OCU410, with Phase III initiation planned for Q3 2026. - Gene therapies and regenerative medicine candidates, including Eyestem's recently approved Phase II cell therapy Eyecyte-RPE, are attracting substantial industry interest for their potential one-time administration benefit.
- Ocugen completed a $22.5 million underwritten registered direct offering of 15 million shares at $1.50 per share, with RTW Investments leading the financing round. - The biotechnology company will use net proceeds of $20.85 million for general corporate purposes and expects the funding to extend its cash runway into the fourth quarter of 2026. - Ocugen is developing modifier gene therapies for inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy affecting millions globally.
- Ocugen's OCU410ST modifier gene therapy demonstrated a 54% reduction in atrophic lesion growth in treated eyes compared to untreated eyes over 12 months in Phase 1 GARDian1 trial results published in Nature Eye. - All treated patients either stabilized or improved in visual acuity, with treated eyes gaining an average of 4.5 letters compared to a 1.5 letter decline in untreated fellow eyes. - The therapy showed a favorable safety profile with no drug-related serious adverse events, supporting advancement to the ongoing Phase 2/3 GARDian3 trial. - OCU410ST represents a paradigm shift from mutation-specific approaches to an agnostic modification strategy that could benefit patients regardless of their underlying ABCA4 mutation.
- Ocugen's board approved a $9.36 million Performance Stock Unit grant for CEO Dr. Shankar Musunuri, with two-thirds contingent on FDA and EMA regulatory milestones through 2028. - The compensation structure directly aligns executive incentives with the success of OCU400 gene therapy for retinitis pigmentosa, which is nearing completion of Phase 3 patient recruitment. - OCU400's pivotal Phase 3 trial liMeliGhT is expected to deliver topline results in Q4 2026, with a Biologics License Application planned for submission during 2026. - The performance-based award reflects the company's critical developmental phase as it approaches potential regulatory submissions for both OCU400 and OCU410 gene therapies.
- The global cell and gene therapy market is expected to exceed $105 billion by 2033, driven by significant expansion in clinical pipelines with Phase I trials experiencing approximately 11% growth. - Cell therapy dominates the market with 61.2% share, reaching $14.66 billion in 2023, while manufacturing costs remain a challenge with CAR-T therapies exceeding $100,000 per patient. - North America leads the market with 43.7% share at $11.97 billion in 2023, supported by advanced regulatory frameworks including the FDA's RMAT designation for accelerated therapy review. - Advanced delivery vectors and viral vector platforms are driving innovation, with companies like AGC Biologics and Charles River Laboratories launching new manufacturing solutions to improve scalability and reduce costs.
- The dry age-related macular degeneration market is expected to experience substantial growth through 2034, driven by the uptake of recently approved therapies and the anticipated launch of emerging treatments. - Multiple innovative therapies are advancing through clinical trials, including Gildeuretinol from Alkeus Pharmaceuticals, which demonstrated a 0.25 sq mm per year reduction in geographic atrophy lesion growth compared to placebo in its Phase II/III SAGA trial. - The United States represents the largest market opportunity with approximately 21 million prevalent cases in 2024, while dry AMD accounts for nearly 90% of all AMD cases, representing a vast untapped therapeutic opportunity.
- Ocugen's stock price increased by 16.5% following the announcement of an exclusive licensing agreement with Kwangdong for OCU400 gene therapy rights in Korea. - The licensing deal represents a significant milestone for Ocugen's gene therapy pipeline, providing market access in the Korean territory for their OCU400 treatment. - Despite the positive market reaction, analysts note ongoing funding needs and clinical risks that continue to present challenges for the biotechnology company. - Community fair value estimates for Ocugen range widely from $0.11 to $6.50 per share, reflecting diverse investor perspectives on the company's prospects.
- Ocugen has executed a licensing agreement with Kwangdong Pharmaceutical for exclusive Korean rights to OCU400, a novel modifier gene therapy for retinitis pigmentosa. - The deal includes upfront fees and development milestones totaling up to $7.5 million, with potential sales milestones of $180 million or more over the first 10 years of commercialization. - OCU400 is currently in Phase 3 clinical development with a target U.S. BLA filing in 2026, representing a potential one-time therapy for life to treat retinitis pigmentosa. - The Korean market represents an estimated 7,000 individuals with retinitis pigmentosa, approximately 7% of the U.S. market size.
